These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 31472732)

  • 21. The Case for Real-world Evidence in the Future of Clinical Research on Chronic Myeloid Leukemia.
    Webster J; Smith BD
    Clin Ther; 2019 Feb; 41(2):336-349. PubMed ID: 30709609
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Value of Real-World Data in Understanding Prostate Cancer Risk and Improving Clinical Care: Examples from Swedish Registries.
    Beckmann K; Garmo H; Franck Lissbrant I; Stattin P
    Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33669624
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sources of Safety Data and Statistical Strategies for Design and Analysis: Real World Insights.
    Marchenko O; Russek-Cohen E; Levenson M; Zink RC; Krukas-Hampel MR; Jiang Q
    Ther Innov Regul Sci; 2018 Mar; 52(2):170-186. PubMed ID: 29714518
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Roles of real-world evidence in severe asthma treatment: challenges and opportunities.
    Lee Y; Lee JH; Park SY; Lee JH; Kim JH; Kim HJ; Kim SH; Chung KF; Song WJ
    ERJ Open Res; 2023 Mar; 9(2):. PubMed ID: 37057082
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Using Real World Data in Cancer Clinical Studies].
    Yamanaka T; Yamazaki K; Hamano T
    Gan To Kagaku Ryoho; 2020 Nov; 47(11):1531-1536. PubMed ID: 33268722
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Application of Real-World Data to External Control Groups in Oncology Clinical Trial Drug Development.
    Yap TA; Jacobs I; Baumfeld Andre E; Lee LJ; Beaupre D; Azoulay L
    Front Oncol; 2021; 11():695936. PubMed ID: 35070951
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characteristic Analysis of Complementary and Alternative Medicine in Randomized Controlled Trials of Oncology: A Comparison of Published Studies.
    Zhang H; Yang G; Zhang W; Gu W; Su Y; Ling C
    Integr Cancer Ther; 2018 Jun; 17(2):551-557. PubMed ID: 28627237
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Balancing the Optimal and the Feasible: A Practical Guide for Setting Up Patient Registries for the Collection of Real-World Data for Health Care Decision Making Based on Dutch Experiences.
    de Groot S; van der Linden N; Franken MG; Blommestein HM; Leeneman B; van Rooijen E; Koos van der Hoeven JJ; Wouters MW; Westgeest HM; Uyl-de Groot CA
    Value Health; 2017 Apr; 20(4):627-636. PubMed ID: 28408005
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aggregated adverse-events outcomes in oncology phase III reports: A systematic review.
    Maillet D; Gan HK; Blay JY; You B; Péron J
    Eur J Cancer; 2016 Jan; 52():26-32. PubMed ID: 26630531
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of anticipated and actual control group outcomes in randomised trials in paediatric oncology provides evidence that historically controlled studies are biased in favour of the novel treatment.
    Moroz V; Wilson JS; Kearns P; Wheatley K
    Trials; 2014 Dec; 15():481. PubMed ID: 25490968
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Opportunities and barriers for the use of Australian cancer registries as platforms for randomized clinical trials.
    Yan MK; Adler NR; Heriot N; Shang C; Zalcberg JR; Evans S; Wolfe R; Mar VJ
    Asia Pac J Clin Oncol; 2022 Aug; 18(4):344-352. PubMed ID: 34811922
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Validation of Real-World Data-based Endpoint Measures of Cancer Treatment Outcomes.
    Li Q; Zhang H; Chen Z; Guo Y; George TJ; Chen Y; Wang F; Bian J
    AMIA Annu Symp Proc; 2021; 2021():716-725. PubMed ID: 35308944
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Estimation of causal effect in integrating randomized clinical trial and observational data - An example application to cardiovascular outcome trial.
    Zhang Y; Lin LA; Starkopf L; Chen J; Wang WWB
    Contemp Clin Trials; 2021 Aug; 107():106492. PubMed ID: 34175491
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Importance and challenges of studying marketed drugs: what is a phase IV study? Common clinical research designs, registries, and self-reporting systems.
    Glasser SP; Salas M; Delzell E
    J Clin Pharmacol; 2007 Sep; 47(9):1074-86. PubMed ID: 17766697
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative effectiveness research: opportunities in surgical oncology.
    Neuman HB; Greenberg CC
    Semin Radiat Oncol; 2014 Jan; 24(1):43-8. PubMed ID: 24314341
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prospects for research in haemophilia with real-world data-An analysis of German registry and secondary data.
    Schopohl D; Bidlingmaier C; Herzig D; Klamroth R; Kurnik K; Rublee D; Schramm W; Schwarzkopf L; Berger K
    Haemophilia; 2018 Jul; 24(4):584-594. PubMed ID: 29488669
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The value of surrogate endpoints for predicting real-world survival across five cancer types.
    Shafrin J; Brookmeyer R; Peneva D; Park J; Zhang J; Figlin RA; Lakdawalla DN
    Curr Med Res Opin; 2016; 32(4):731-9. PubMed ID: 26743800
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Premature trial discontinuation often not accurately reflected in registries: comparison of registry records with publications.
    Alturki R; Schandelmaier S; Olu KK; von Niederhäusern B; Agarwal A; Frei R; Bhatnagar N; Hooft L; von Elm E; Briel M
    J Clin Epidemiol; 2017 Jan; 81():56-63. PubMed ID: 27614277
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pilot test for linking population-based cancer registries with CCG/POG pediatric registries.
    Ross F
    J Ky Med Assoc; 2002 May; 100(5):195-9. PubMed ID: 12040910
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.